Cel Sci Corporation (CVM)

[alexander77]

All statistical calculations are wrong, because it is a double blinded RANDOMISED trial:
—> stage 3 and 4a patients are not equally divided among SOC vs MK+SOC, and we all know stage 4a patients have less overall survival expectancy than stage 4a patients
—> the number of patients aren’t equally divided between all cancer centers. I am not telling news if I say that standard of care surgery in the U.S. is better than in India eg, and that the hygiene is better in the U.S. with less bacterial implications. I can give more examples of the benefit with living luxurious in the U.S. and Western Europe vs Africa/parts of Asia and Eastern Europe on the survival chances in cancer.

Your statistiscal spreadsheet can be used as a good guidance but nothing more, because it is RANDOMISED.
We are only sure of four things:
1. that Multikine has shown to reduce - and sometimes even eliminate - the tumor size
2. that Multikine has survived two interim data monitoring boards on efficacy and safety.
3. TEVA and Orient pharma have NEVER EVER quit their partnership on the Multikine trial
4. Not a single institution decided to sell shares since September 2018. Instead there was only increase in institutional ownership.

My Personal price target is $80/share (or $4B market cap)